Pertuzumab (Perjeta) for HER2-positive metastatic breast cancer

Medical Letter on Drugs and Therapeutics

Volumn 54, Issue 1395, 2012, Pages 58-59

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERTUZUMAB; PLACEBO; TRASTUZUMAB;

ALOPECIA; ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CELL GROWTH; CELL SURVIVAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG APPROVAL; DRUG COST; DRUG DOSAGE FORM; DRUG ERUPTION; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LETTER; METASTASIS; MORTALITY; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; SIDE EFFECT;

EID: 84868606550     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. KA Cronin et al. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest 2010; 28:963.
2. KS Saini et al. Beyond trastuzumab: new treatment options for HER2-positive breast cancer. Breast 2011; 20 (Suppl 3): S20
3. A Awada et al. New therapies in HER2-positive breast cancer: a major step towards a cure of the disease. Cancer Treat Rev 2012; 38:494.
4. J Baselga et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109.
5. Wholesale acquisition cost (WAC) according to the manufacturer